CombiGene AB publishes Annual Report for 2018
The auditor’s review report states the following:
Regarding auditors remark of the Annual Report 2018
In September 2018 a unit issue was carried out. Since issue approval by the board did not include warrants, but only shares, the unit issue was introduced on incorrect assumptions and hence was in violation of Section 42, Chapter 8 of the Swedish Companies Act. When the error was noted, the board acted immediately, calling an extraordinary meeting of shareholders in October 2018, which approved the issue of warrants. The company incurred no financial loss, as the cost was borne by an advisor to the company.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.